In 2026, around 85 percent of all forecasted revenue generated by COVID-19 vaccines is expected to be generated by mRNA vaccines. This statistic illustrates the forecasted share of COVID-19 vaccine revenues by technology.

According to a forecast as of March, BioNTech's and Pfizer's vaccine against COVID-19 could generate sales revenues of nearly 22 billion U.S. dollars during 2021. The BioNTech/Pfizer vaccine was the first COVID-19 vaccine to be widely approved and used. German biotech company BioNTech saw a 156 percent growth in its shares in the last 12 months as of March 2021.

Will Moderna be the big winner? Moderna is expected to be the company with the largest sales revenues from a COVID-19 vaccine. Forecasts predict that the company will make around 43 billion U.S. dollars in sales through its vaccine. Interestingly, Moderna was established in 2010 and had never made profit before the pandemic. Thus, the development of the covid vaccine based on the latest mRNA technology will mark a definitive breakthrough for the Massachusetts-based biotech company. Moderna received significant funding through taxpayer money as well as help in research and development from the National Institutes of Health.

Vaccine pricing in a pandemic Drug pricing is always a big issue and this was also the case with COVID-19 vaccines. While some companies, like AstraZeneca, stated early on that prices for the vaccine will be on a non-profit base at least as long as the pandemic is ongoing, others took a more profit-oriented approach. However, even these companies state that their current prices are low special prices, taking into account urgent public health interests, which normally would be much higher. According to several projections, COVID-19 drugs and vaccines could establish a market worth some 40 billion U.S. dollars annually.

In 2021, COVID-19 vaccine Comirnaty produced by Biontech and Pfizer is expected to make 36 billion U.S. dollars in sales worldwide, while Moderna's mRNA-1273 vaccine is expected to make (15 to) 18 billon U.S. dollars. This statistic illustrates the forecasted sales of select major COVID-19 vaccines worldwide in 2021 and 2022.

Global Coronavirus Vaccine market size 2025 was XX Million. Coronavirus Vaccine Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Moderna generated total revenues of some 3.2 billion U.S. dollars in 2024, a massive decrease compared to the years before. The drop was mainly due to the decreasing demand for its COVID-19 vaccine Spikevax. Working hard to produce the first 'blockbuster' Moderna is a clinical stage biotech company that is pioneering messenger RNA (mRNA) therapeutics and vaccines. Beside its COVID-19 vaccine, the company is yet to generate revenues from the sale of potential drugs, and this will remain the same until it successfully completes clinical development and obtains regulatory approval for one of its medicines. Like many other biotech companies, Moderna invests significant amounts of money into research and development projects, and annual costs continue to grow. One of the very first COVID-19 vaccines approved Moderna, in partnership with the National Institutes of Health (NIH) and the Coalition for Epidemic Preparedness Innovations (CEPI), was one of the very first to develop a vaccine to fight COVID-19. The vaccine codenamed mRNA-1273 – designed and manufactured in only 25 days – prevents future infections of the novel coronavirus that has caused the pandemic. The Moderna vaccine successfully went through all necessaryclinical phases, and was the second vaccine - after the Biontech/Pfizer vaccine - to be approved for widely usage already in late 2020.

Moderna experiences a substantial financial loss in Q4 2024, with vaccine sales underperforming amid global market challenges.

GlaxoSmithKline generated approximately 9.3 billion U.S. dollars from vaccine sales in 2021, making it the sixth largest vaccine company in the world based on revenue. Before the pandemic and the appearance of COVID-19 vaccines, the British pharmaceutical giant used to be the global leader in vaccines.

Analyzing vaccine sales of leading companies GlaxoSmithKline reported an annual revenue of 34.1 billion British pounds in 2021 – vaccine sales accounted for around 20 percent of that figure. Year-on-year sales of Shingrix, the company’s shingles vaccine, more than doubled to almost two billion British pounds in 2020. The leading vaccine of Merck & Co. is Gardasil/Gardasil 9, which can help in the prevention of certain cancers. The vaccine is one of Merck’s top-selling products and accounted for more than half of the company’s total vaccine sales. Pfizer generated vaccine sales of nearly 43 billion U.S. dollars in 2021, of course heavily boosted by its COVID-19 vaccine sales. The pneumococcal vaccine Prevnar 13/Prevenar 13 was the company’s second product based on revenue during that year.

The race for a coronavirus vaccine Until recently, and despite growth in the global vaccine market, there were only four big pharma companies with substantial vaccine operations. However, the COVID-19 pandemic has highlighted the critical importance of vaccine research and development. Aided by government funding and partnerships, several smaller companies were among the first to enter the race to find vaccines and treatments for the disease. Biotech company Moderna, by applying its pioneering mRNA research to the problem, was among the first to bring a safe and effective COVID-19 vaccine to the broader market.

Factors associated with taking a booster shot (those who had a COVID-19 vaccine before, n = 182,843,937).

Factors associated with taking a COVID-19 vaccine (male only n = 117,585,236).

In 2024, basic earnings per share of biotech company BioNTech SE stood at around -2.8 euros, compared to around 39 euros back in 2022. This statistic illustrates the annual earnings per share of BioNTech SE from 2017 to 2024. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.

COVID-19 vaccination has significantly decreased morbidity, hospitalizations, and death during the pandemic. However, disparities in vaccination uptake threatens to stymie the progress made in safeguarding the health of Americans. Using a nationally representative adult (≥18 years old) sample from the 2021 Medical Expenditure Panel Survey (MEPS), we aimed to explore disparities in COVID-19 vaccine and booster uptake by income levels. To reflect the nature of the survey, a weighted logistic regression analysis was used to explore factors associated with COVID-19 vaccine and booster uptake. A total of 241,645,704 (unweighted n=21,554) adults were included in the analysis. Average (SD) age of the population was 49 (18) years old, and 51% were female. There were disparities in COVID-19 vaccine and booster uptake by income groups. All other income groups were less likely to receive COVID-19 vaccines and booster shot than those in the high-income group. Those in the poor income group had 55% lower odds of being vaccinated for COVID-19 (aOR=0.45, p

BackgroundThe rapid development and rollout of COVID-19 vaccines helped reduce the pandemic’s mortality burden. The vaccine rollout, however, has been uneven; it is well known that vaccination rates tend to be lower in lower income countries. Vaccine uptake, however, ultimately depends on the willingness of individuals to get vaccinated. If vaccine confidence is low, then uptake will be low, regardless of country income level. We investigated the impact on country-level COVID-19 vaccination rates of both national income and vaccine hesitancy.MethodsWe estimated a linear regression model of COVID-19 vaccine uptake across 145 countries; this cross-sectional model was estimated at each of four time points: 6, 12, 18, and 24 months after the onset of global vaccine distribution. Vaccine uptake reflects the percentage of the population that had completed their primary vaccination series at the time point. Covariates include per capita GDP, an estimate of the percentage of country residents who strongly disagreed that vaccines are safe, and a variety of control variables. Next, we estimated these models of vaccine uptake by country income (countries below, and above the international median per capita GDP) to examine whether the impact of vaccine hesitancy varies by country income.ResultsWe find that GDP per capita has a pronounced impact on vaccine uptake at 6 months after global rollout. After controlling for other factors, there was a 22 percentage point difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by per capita GDP; this difference grew to 38% by 12 months. The deleterious impact of distrust of vaccine safety on vaccine uptake became apparent by 12 months and then increased over time. At 24 months, there was a 17% difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by distrust. The income stratified models reveal that the deleterious impact of vaccine distrust on vaccine uptake at 12 and 24 months is particularly evident in lower income countries.ConclusionsOur study highlights the important role of both national income and vaccine hesitancy in determining COVID-19 vaccine uptake globally. There is a need to increase the supply and distribution of pandemic vaccines to lower-income countries, and to take measures to improve vaccine confidence in these countries.

As of September 2021, lower-middle-income countries had around 43 percent of the total world population, but only accounted for around 22 percent of COVID-19 vaccine doses administered globally. This statistic illustrates the percentage of COVID-19 vaccine doses administered worldwide as of September 10, 2021, by country income group.

Global Covid 19 Vaccine Bottle market size 2025 is $1669.45 Million whereas according out published study it will reach to $3363.28 Million by 2033. Covid 19 Vaccine Bottle market will be growing at a CAGR of 9.15% during 2025 to 2033.

Replication files for results in "Addressing Vaccine Hesitancy: Experimental Evidence from Nine High-Income Countries during the COVID-19 Pandemic" published in British Journal of Medicine, Global Health

BackgroundVaccination is the most effective method to prevent the spread of infectious diseases. Nevertheless, vaccine hesitancy has been an issue. Parental hesitancy toward vaccines is a major part of the problem. COVID-19 vaccine acceptance is no different, it poses another challenge in facing the pandemic. In Low- and Middle-Income Countries (L&MICs) several studies measured parents' acceptance to vaccinate their children against COVID-19 and resulted in different acceptance proportions.AimsThe paper aims at obtaining a precise estimate of the overall proportion of L&MICs' parents accepting to vaccinate their children against COVID-19 and identifying the main determinant of their decisions.MethodsThis meta-analysis follows the PRISMA 2020 statement on updated guidelines and the checklist for reporting systematic reviews. Studies published between December till February 2022 were assessed for inclusion. The final effect size (i.e., the proportion of parents in L&MICs accepting to vaccinate their children against COVID-19) was measured using the Arcsine proportions method. Analysis was done using R program.ResultsThe proportion of parents in L&MICs accepting to vaccinate their children against COVID-19 is 49%. The major reason for their acceptance is their belief that COVID-19 vaccine is fundamental to the fight against the pandemic while the most common factor for parents' hesitancy to vaccinate their children against COVID-19 is their concerns about vaccine efficacy, safety, and possible side effects.ConclusionThe proportion of parents in L&MICs accepting to vaccinate their children against COVID-19 is lower than the global level. To increase parental acceptance, responsible authorities should concentrate on increasing their population's trust in the government and in vaccine manufacturers. As well as concentrating on increasing acceptance of the vaccine idea in general.

Vaccine Administration Market Outlook

The global vaccine administration market size was estimated at USD 5.2 billion in 2023 and is projected to reach USD 11.4 billion by 2032, with a compound annual growth rate (CAGR) of 9.1%. This impressive growth is driven by several factors, including advancements in vaccine delivery technologies, increased vaccination efforts worldwide, and rising awareness about the importance of immunizations.

One of the primary growth factors for the vaccine administration market is the ongoing global effort to eradicate infectious diseases through widespread immunization programs. Governments and health organizations worldwide have been emphasizing the importance of vaccination, leading to increased vaccine coverage and administration rates. The COVID-19 pandemic has further accentuated the critical role of vaccinations, thereby boosting the market growth. The introduction of novel vaccines and booster doses has necessitated advancements in vaccine delivery systems, contributing to the overall market expansion.

Technological advancements in vaccine administration devices have significantly spurred market growth. Innovations such as needle-free jet injectors, intranasal devices, and improved syringe designs have enhanced the efficiency, safety, and patient compliance of vaccine administration. These advancements reduce the risk of needle-stick injuries, minimize vaccine wastage, and improve the overall vaccination experience. Moreover, the increasing adoption of smart syringes with integrated tracking and safety features aligns with global efforts to ensure vaccine integrity and monitoring.

The collaboration between public and private sectors has been a significant driver in the vaccine administration market. Public health initiatives, partnerships with pharmaceutical companies, and funding from international organizations have bolstered the production, distribution, and administration of vaccines. Financial support for vaccine research and development has accelerated the introduction of new vaccines, creating a robust pipeline for future market growth. Additionally, government policies and reimbursement frameworks have made vaccines more accessible, particularly in low- and middle-income countries, further propelling market expansion.

The regional outlook for vaccine administration is highly promising, with considerable growth anticipated across various geographies. North America, driven by high healthcare expenditure and robust immunization programs, holds a significant market share. The Asia Pacific region is expected to showcase the highest growth rate due to rising healthcare investments, large population base, and increasing awareness regarding vaccine-preventable diseases. Europe also presents substantial growth opportunities, supported by strong government initiatives and advanced healthcare infrastructure. Latin America and the Middle East & Africa, though currently smaller markets, are poised for notable growth due to improving healthcare access and ongoing immunization campaigns.

Product Type Analysis

The vaccine administration market can be segmented by product type into syringes, jet injectors, intranasal devices, and others. Syringes remain the most widely used device for vaccine administration due to their cost-effectiveness, simplicity, and widespread availability. The advancements in syringe technology, such as auto-disable and prefilled syringes, have enhanced safety, reduced contamination risks, and minimized vaccine wastage. The dominance of syringes in the market is further reinforced by their extensive use in routine immunization programs and emergency vaccination drives globally.

Jet injectors represent an innovative leap in the vaccine delivery landscape, offering needle-free administration that improves patient compliance and reduces needle-associated risks. These devices use high-pressure streams to deliver vaccines through the skin, eliminating the need for needles and enhancing the overall vaccination experience. Jet injectors are particularly beneficial in mass immunization settings and for individuals with needle phobia. Their growing popularity is driven by ongoing technological advancements and increasing acceptance among healthcare providers and patients alike.

Intranasal devices have emerged as a promising alternative for vaccine administration, especially for respiratory infections. These devices deliver vaccines directly to the nasal mucosa, eliciting both systemic and mucosal immunity. The ease of administration, coupled with the potential for self-administ

This statistic depicts revenues of pharmaceutical company Pfizer from 2022 to 2024, by segment. The Primary Care segment, which includes the COVID-19 vaccine Comirnaty, is the company's ********* segment. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to form a new joint venture in 2019, only the Biopharma segment remained.

Global COVID 19 Vaccine Transportation market size 2025 was XX Million. COVID 19 Vaccine Transportation Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Johnson & Johnson was the pharmaceutical company that spent the most in COVID-19 digital advertising spending in the United States between January 1 and May 6, 2021. The company's spending amounted to 29.1 million U.S. dollars. Pfizer followed with 21.5 million. The launch of Pfizer's mRNA vaccine in early December 2020 helped the pharma giant's revenue during the first quarter of 2021 surge 45 percent from its revenue during the first quarter of 2020.